A Phase 3 clinical trial studying rimegepant was listed as recruiting as of September 25, 2026. The trial, registered as NCT07729462, is titled "A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine."
According to the registration, the study is currently in the recruitment phase. No results or outcomes have been posted for this trial at this time. The trial is classified as Phase 3, which typically involves larger patient populations to further evaluate a study medicine.
This update reflects only the trial's current status as recorded in its public registration. No efficacy or safety conclusions can be drawn from a recruiting status alone. Further updates may be issued as the trial progresses through its phases.
Readers interested in calcitonin, which holds approved regulatory status, may wish to review its compound overview for additional context and background information.